RecruitingNot ApplicableNCT06981754

Dexamethasone Palmitate for PONV After Minimally Invasive Endoscopic Surgery

Intravenous Dexamethasone Palmitate for Prophylaxis of Postoperative Nausea and Vomiting After Minimally Invasive Endoscopic Surgery

Sponsor

Beijing Tiantan Hospital

Enrollment

588 participants

Start Date

Jun 17, 2025

Study Type

INTERVENTIONAL

Conditions

Postoperative nausea and vomiting Dexamethasone Palmitate Minimally Invasive Endoscopic Procedures

Summary

Dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (PONV) prevention. However, PONV is still a complex problem to be solved; for example, even with preoperative dexamethasone administration, 14.0-26.3% of patients undergoing minimally invasive endoscopic procedures still experience PONV within 24 hours postoperatively. Compared to dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, 2-5 times that of traditional water-soluble dexamethasone, with fewer adverse effects. This trial aims to assess the effect and safety of preoperative dexamethasone palmitate on PONV after surgery.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria3

Aged 18 to 65 years;
Providing written informed consent;
Patients scheduled to undergo elective minimally invasive endoscopic surgery (laparoscopic or thoracoscopic surgery) under general anaesthesia.

Exclusion Criteria6

Known to be allergic to dexamethasone;
Any systemic glucocorticoids within 3 months before trial entry;
History of severe heart disease, liver/kidney failure, or systemic rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, et al);
Cognitive impairment or severe mental illness;
Uncontrolled diabetes or infectious diseases;
Pregnancy or breastfeeding.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDexamethasone palmitate

Patients in the dexamethasone palmitate group will be assigned to receive intravenous injection of dexamethasone palmitate 8 mg (contains 5mg dexamethasone) after anesthesia induction and before surgical incision.

DRUGDexamethasone

Patients in the dexamethasone group will be assigned to receive intravenous injections of dexamethasone 5 mg after anesthesia induction and before surgical incision.